$MRTX News
Last published 2y ago
- 2y agoMRTXApproval of Krazati, Nda #216340 (Efficacy)FDA Approved DrugsApproval Date: 06/21/2024; Drug Name: Krazati, Nda #216340; Active Ingredients: ADAGRASIB; Company: Mirati Theraps; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 216340
- 2y agoMRTXEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationPR NewswireMirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted...
- 2y agoONCYEXELMRTXLLY+1Improving Survival Rates: Biotech Innovations in Pancreatic Cancer TreatmentPR NewswireUSA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a...
- 2y agoPCTIMRTXCSTRBBAIMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 3y agoMRTXMirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedurePR NewswireMirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the...
- 3y agoMRTXMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesPR NewswireMirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023...
- 3y agoMRTXMirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationPR NewswireMirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare...
- 3y agoKURAMRTXKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCGlobeNewswireSAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and
- 3y agoPNTVERYMRTXORTXMoore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 3y agoMRTXMRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers SquibbGlobeNewswireMONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (NASDAQ:MRTX) ("Mirati") to Bristol Myers Squibb
- 3y agoMRTXORTXSPSRTMoore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoMRTXMirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)PR NewswireMirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study ...
- 3y agoSPOTZSMRTXTSLA+12Stocks making the biggest moves midday: General Dynamics, United Airlines, Spotify and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoDISZSXOMSPOT+7Stocks making the biggest moves premarket: Exxon Mobil, Lockheed Martin, Walt Disney and moreCNBCThese are the stocks posting the largest moves in early trading.
- 3y agoBMYMRTXBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati TherapeuticsBusiness WireBristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a
- 3y agoMRTXMirati To Present Updated Clinical Data at ESMO Congress 2023PR NewswireLate-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor
- 3y agoBNTXINCYMACKMRTX+1Pancreatic Cancer Battle Boosted by $200M VC FirmPR NewswireFN Media Group Presents USA News Group News Commentary
- 3y agoMRTXMirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung CancerPR NewswireSAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis
- 3y agoMRTXMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant
- 3y agoMRTXMirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare ConferencePR NewswireSAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, will participate at the Morgan Stanley 21st Annual Global Healthcare Conference on
- 3y agoMRTXMirati Therapeutics Announces Departure of Chief Financial Officer Laurie StelzerPR NewswireSAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on
- 3y agoMRTXMirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung CancerPR NewswireSAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase
- 3y agoMRTXMirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireSAN DIEGO, Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the closing of its previously announced underwritten public offering of
- 3y agoMRTXCancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 InhibitionPR NewswireThe detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that blocking PRMT5-MTA complex is a rational and differentiated approach to treat cancers harboring MTAP deletion Partial responses
- 3y agoMRTXMirati Therapeutics Announces Pricing of Upsized Public OfferingPR NewswireSAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the pricing of an underwritten public offering of 9,669,631 shares of its common
- 3y agoMRTXMirati Therapeutics Announces Proposed Public OfferingPR NewswireSAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that it intends to offer and sell $250.0 million of shares of its common stock,
- 3y agoMRTXMirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesPR NewswireShares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in
- 3y agoMRTXMirati Therapeutics Announces Departure of Chief Executive Officer David MeekPR NewswireCharles M. Baum, M.D., Ph.D. assumes role of interim CEO SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company today announced that David Meek
- 3y agoMRTXMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Aug. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to a new employee with a grant date
- 3y agoMRTXMirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023PR NewswireSAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates
- 3y agoMRTXMirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C MutationPR NewswireSAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency's (EMA) Committee
- 3y agoMRTXMirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent DirectorPR NewswireSAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol
- 3y agoAGLEMRTXONCYPOAI+1Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New DrugsPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 22, 2023 /PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and
- 3y agoMRTXJournal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) MetastasesPR NewswireAdagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial (IC) activity in KRASG12C-mutated NSCLC with untreated CNS metastases Data demonstrate compelling clinical activity;
- 3y agoMRTXMirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023PR NewswireSAN DIEGO, June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June
- 3y agoMRTXMirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual MeetingPR NewswireData follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers Additional Company Presentations Highlight Real-World Observations in Patients Living with Metastatic NSCLC and KRASG12C Mutated
- 3y agoMRTXMirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®PR NewswireSAN DIEGO, May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at
- 3y agoMRTXMirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoMRTXMirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesPR NewswireSAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and
- 3y agoMRTXMirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical StudiesPR NewswireSAN DIEGO and NASHVILLE, Tenn., May 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, and Sarah Cannon Research Institute (SCRI), one of the world's
- 3y agoMRTXMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, May 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 2 new employees with a grant
- 3y agoMRTXJournal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid TumorsPR NewswireData demonstrates compelling clinical activity, highlights adagrasib potential as monotherapy in solid tumors Clinical data also presented at the ASCO Plenary Series: April 2023 Session Data follows recent inclusion of
- 3y agoMRTXMirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023PR NewswireSAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates
- 3y agoMRTXMirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage ProgramsPR NewswirePreclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage
- 3y agoMRTXMirati Therapeutics to Participate at the Barclays Global Healthcare ConferencePR NewswireSAN DIEGO, March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. /
- 3y agoMRTXMirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesPR NewswireSAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent
- 3y agoMRTXMirati Therapeutics to Participate at the 43rd Annual Cowen Health Care ConferencePR NewswireSAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a targeted oncology company, will participate at the 43rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m.
- 3y agoMRTXMirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023PR NewswireSAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate
- 3y agoMRTXMirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR NewswireSAN DIEGO, Feb. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 4 new employees with a grant date of
- 3y agoMRTXMirati Therapeutics to Participate in Two Upcoming Healthcare ConferencesPR NewswireSAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences. Wednesday, February 8 at 7:45 a.m. PT / 10:45